🟢 Damora Therapeutics, Inc. is trading 5.55% up today after TD Cowen initiated coverage with a Buy rating

Damora Therapeutics, Inc. is trading at $22.07 (+5.55%) after TD Cowen initiated coverage with a Buy rating on June 8, 2026.

• The move follows renewed analyst confidence in the company’s clinical pipeline, specifically its lead asset DMR-001 for the treatment of rare blood disorders.
• Broader U.S. markets are also firmer, with the Nasdaq up 1.13%, which may be providing additional support for the stock.